Systemic sclerosis (SSc) is a multi-organ fibrotic disease with few treatment options. Activated fibroblasts are the key effector cells in SSc responsible for the excessive production of collagen and the development of fibrosis. PDGF, a potent mitogen for cells of mesenchymal origin, has been implicated in the activation of SSc fibroblasts. Our aim was to examine the therapeutic potential of crenolanib, an inhibitor of PDGF receptor signaling, in cultured fibroblasts and in angiotensin II (Ang II)-induced skin and heart fibrosis. Crenolanib effectively inhibited proliferation and migration of SSc and healthy control (HC) fibroblasts, and attenuated basal and TGF-β-induced expression of CCN2/CTGF and periostin. In contrast to HC fibroblasts, SSc fibroblasts proliferated in response to PDGFAA, while a combination of PDGFAA and CCN2 was required to elicit a similar response in HC fibroblasts. Importantly, PDGFRα mRNA correlated with CCN2 and other fibrotic markers in the skin of SSc patients. In mice challenged with Ang II, PDGFRα-positive cells were increased in the skin and heart. These PDGFRα-positive cells co-localized with PDGFRβ, procollagen and periostin. Treatment with crenolanib attenuated the skin and heart fibrosis. Our data indicate that inhibition of PDGF signaling presents an attractive therapeutic approach for SSc.